At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 15 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05003388Phase 1RecruitingUpdate OverdueUpdated 14mo ago · Completion was 8mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Aug 12, 2021·Updated Apr 8, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Multiple Sclerosis. Currently recruiting, targeting 15 participants across 2 sites in 2 countries.
Signals
Enrollment appears stalled
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of multiple sclerosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesAntigua and Barbuda, Greece
Collaborators--
Timeline
Phase 1RecruitingOverdue
20222023202420252026
Enrollment StartJun 2021
First PostedAug 2021
Primary CompletionOct 2025
TodayJul 2026
First PostedAug 12, 2021
Enrollment StartJun 26, 2021
Primary CompletionOct 1, 2025
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 4.9 years ago
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells